ClinicalTrials.gov
ClinicalTrials.gov Menu

Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke (SPARCL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00147602
Recruitment Status : Completed
First Posted : September 7, 2005
Last Update Posted : April 22, 2015
Sponsor:
Information provided by:
Pfizer

Brief Summary:
To determine whether Lipitor reduces stroke, compared to placebo in patients who have had a previous stroke or transient ischemic attack.

Condition or disease Intervention/treatment Phase
Cardiovascular Disease Drug: atorvastatin Phase 4

Study Type : Interventional  (Clinical Trial)
Enrollment : 4732 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo- Controlled Study Of Atorvastatin As Prevention Of Cerebrovascular Events In Patients With A Previous Transient Ischemic Attack (TIA) Or Stroke
Study Start Date : November 1998
Study Completion Date : November 2005

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Time to occurrence of fatal or non-fatal stroke

Secondary Outcome Measures :
  1. Time to occurrence of an acute coronary event, consisting of cardiac death, nonfatal myocardial infarction, resuscitated cardiac arrest or unstable angina.
  2. Time to occurrence of a cerebrovascular event, defined as fatal or nonfatal stroke or TIA.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Previous stroke or TIA

Exclusion Criteria:

  • coronary heart disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00147602


  Hide Study Locations
Locations
Australia, New South Wales
Pfizer Investigational Site
East Gosford, New South Wales, Australia, 2250
Pfizer Investigational Site
Randwick, Sydney, New South Wales, Australia, 2031
Australia, Victoria
Pfizer Investigational Site
Footscray, Victoria, Australia, 3011
Pfizer Investigational Site
Heidelberg Heights, Victoria, Australia, 3081
Pfizer Investigational Site
Parkville, Victoria, Australia, 3050
Pfizer Investigational Site
Prahran, Victoria, Australia, 3181
Australia, Western Australia
Pfizer Investigational Site
Perth, Western Australia, Australia, 6000
Austria
Pfizer Investigational Site
Graz, Austria, A-8036
Pfizer Investigational Site
Innsbruck, Austria, A-6020
Pfizer Investigational Site
Villach, Austria, A-9504
Pfizer Investigational Site
Wien, Austria, 1160
Belgium
Pfizer Investigational Site
Gent, Belgium, 9000
Pfizer Investigational Site
Leuven, Belgium, 3000
Pfizer Investigational Site
Tielt, Belgium, 8700
Pfizer Investigational Site
Waregem, Belgium, 8790
Brazil
Pfizer Investigational Site
Porto Alegre, RS, Brazil, 90610-000
Pfizer Investigational Site
Sao Paulo, SP, Brazil, 05403-000
Chile
Pfizer Investigational Site
Vina Del Mar, Chile
Czech Republic
Pfizer Investigational Site
Brno, Czech Republic, 65691
Pfizer Investigational Site
Ostrava-Poruba, Czech Republic, 70852
Pfizer Investigational Site
Ostrava, Czech Republic, 70384
Pfizer Investigational Site
Pilsen, Czech Republic, 30599
Pfizer Investigational Site
Prague 4, Czech Republic, 14021
Pfizer Investigational Site
Zlin, Czech Republic, 76275
Denmark
Pfizer Investigational Site
Copenhagen Nv, Denmark, 2400
Pfizer Investigational Site
Glostrup, Denmark, 2600
Pfizer Investigational Site
Hellerup, Denmark, 2900
Finland
Pfizer Investigational Site
Hus, Helsinki, Finland, 00029
Pfizer Investigational Site
Kotka, Finland, 48210
Pfizer Investigational Site
Kuopio, Finland, 70210
Pfizer Investigational Site
Lahti, Finland, 15850
Pfizer Investigational Site
Lappeenranta, Finland, 53130
Pfizer Investigational Site
Oulu, Finland, 90220
France
Pfizer Investigational Site
Saint Denis, Cedex 1, France, 93205
Pfizer Investigational Site
Paris, Cedex 20, France, 75970
Pfizer Investigational Site
Toulouse, Cedex 3, France, 31059
Pfizer Investigational Site
Bourg En Bresse, Cedex, France, 01012
Pfizer Investigational Site
Besancon, France, 25030
Pfizer Investigational Site
Marseille, France, 13385
Pfizer Investigational Site
Nice, France, 06000
Pfizer Investigational Site
Paris, France, 75018
Germany
Pfizer Investigational Site
Bad Rodach, Germany, 96476
Pfizer Investigational Site
Berlin, Germany, 10117
Pfizer Investigational Site
Essen, Germany, 45122
Pfizer Investigational Site
Heidelberg, Germany
Pfizer Investigational Site
Leipzig, Germany, 04103
Pfizer Investigational Site
Mannheim, Germany, 69135
Pfizer Investigational Site
Minden, Germany, 32427
Pfizer Investigational Site
Muenchen, Germany, 81377
Pfizer Investigational Site
Muenchen, Germany, 81545
Pfizer Investigational Site
Muenchen, Germany, 81675
Pfizer Investigational Site
Muenster, Germany, 48149
Pfizer Investigational Site
Regensburg, Germany, 93053
Greece
Pfizer Investigational Site
Athens, Melissia, Greece, 15127
Pfizer Investigational Site
Athens, Greece, 11527
Pfizer Investigational Site
Athens, Greece, 15127
Pfizer Investigational Site
Thessaloniki, Greece, 54636
Pfizer Investigational Site
Thessaloniki, Greece, 57010
Israel
Pfizer Investigational Site
Haifa, Israel, 34362
Pfizer Investigational Site
Holon, Israel, 58100
Pfizer Investigational Site
Petach-tikva, Israel, 49372
Pfizer Investigational Site
Tel Aviv, Israel
Italy
Pfizer Investigational Site
Via Brunamonti 15, Perugia, Italy, 06122
Pfizer Investigational Site
Bari, Italy, 70124
Pfizer Investigational Site
Bergamo, Italy, 24128
Pfizer Investigational Site
Genova, Italy, 16132
Pfizer Investigational Site
Milano, Italy, 20132
Pfizer Investigational Site
Monza, Italy, 20052
Mexico
Pfizer Investigational Site
Monterrey, Nuevo Leon, Mexico, 64460
Netherlands
Pfizer Investigational Site
Rotterdam, GD, Netherlands, 3015
Pfizer Investigational Site
Almelo, Netherlands, 7609 PP
Pfizer Investigational Site
Delft, Netherlands, 2625 AD
Pfizer Investigational Site
Goes, Netherlands, 4462 RA
Pfizer Investigational Site
RB Groningen, Netherlands, 9700
Pfizer Investigational Site
Tilburg, Netherlands, 5022 GC
New Zealand
Pfizer Investigational Site
Takapuna, Auckland, New Zealand
Pfizer Investigational Site
Auckland, New Zealand
Pfizer Investigational Site
Christchurch, New Zealand
Poland
Pfizer Investigational Site
Bialystok, Poland, 15-276
Pfizer Investigational Site
Krakow, Poland, 31-503
Pfizer Investigational Site
Lublin, Poland, 20-954
Pfizer Investigational Site
Poznan, Poland, 30-355
Pfizer Investigational Site
Sosnowiec, Poland, 41-200
Pfizer Investigational Site
Warszawa, Poland, 01-211
Pfizer Investigational Site
Warszawa, Poland, 02 - 957
Pfizer Investigational Site
Wroclaw, Poland, 50-420
Portugal
Pfizer Investigational Site
Coimbra Codex, Portugal, 3049
Pfizer Investigational Site
Lisboa, Portugal, 1600
Pfizer Investigational Site
Porto, Portugal, 4000
Slovakia
Pfizer Investigational Site
Bratislava, Slovakia, 81369
Pfizer Investigational Site
Bratislava, Slovakia, 83301
South Africa
Pfizer Investigational Site
Bloemfontein, South Africa, 9301
Pfizer Investigational Site
Cape Town, South Africa, 7800
Pfizer Investigational Site
Parow, South Africa, 7505
Spain
Pfizer Investigational Site
L'Hospitalet (BCN), Barcelona, Spain, 08907
Pfizer Investigational Site
Málaga, Malaga, Spain, 29010
Pfizer Investigational Site
Alicante, Spain, 03010
Pfizer Investigational Site
Barcelona, Spain, 08035
Pfizer Investigational Site
Barcelona, Spain, 08036
Pfizer Investigational Site
Burgos, Spain, 09005
Pfizer Investigational Site
Girona, Spain, 17007
Pfizer Investigational Site
Madrid, Spain, 28006
Pfizer Investigational Site
Madrid, Spain, 28040
Pfizer Investigational Site
Madrid, Spain, 28046
Pfizer Investigational Site
Palma de Mallorca, Spain, 07014
Pfizer Investigational Site
Sevilla, Spain, 41009
Pfizer Investigational Site
Sevilla, Spain, 41013
Pfizer Investigational Site
Sevilla, Spain, 41014
Pfizer Investigational Site
Valencia, Spain, 46009
Pfizer Investigational Site
Zaragoza, Spain, 50009
Sweden
Pfizer Investigational Site
Danderyd, Sweden, 18288
Pfizer Investigational Site
Stockholm, Sweden, 11281
Pfizer Investigational Site
Stockholm, Sweden, 17176
Pfizer Investigational Site
Umea, Sweden, 90185
Pfizer Investigational Site
Uppsala, Sweden, 75185
Pfizer Investigational Site
Vaestervik, Sweden, 59381
Switzerland
Pfizer Investigational Site
Aarau, Switzerland, 5001
Pfizer Investigational Site
Basel, Switzerland, 4031
Pfizer Investigational Site
Bern, Switzerland, 3010
Pfizer Investigational Site
Lausanne, Switzerland, 1011
Pfizer Investigational Site
Zurich, Switzerland, 8091
United Kingdom
Pfizer Investigational Site
Dundee, Scotland, United Kingdom, DD1 9SY
Pfizer Investigational Site
Newport, South Wales, United Kingdom, NP20 4SZ
Pfizer Investigational Site
Aberdeen, United Kingdom, AB25 2ZN
Pfizer Investigational Site
Cardiff, United Kingdom, CF4 4XW
Pfizer Investigational Site
Glasgow, United Kingdom, G11 6NT
Pfizer Investigational Site
Liverpool, United Kingdom, L9 7AL
Pfizer Investigational Site
Nottingham, United Kingdom, NG5 1PB
Pfizer Investigational Site
Woolwich, United Kingdom, SE18 4HQ
Venezuela
Pfizer Investigational Site
Caracas, Venezuela, 1041
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer

Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00147602     History of Changes
Other Study ID Numbers: 0981-342
A2581138
First Posted: September 7, 2005    Key Record Dates
Last Update Posted: April 22, 2015
Last Verified: April 2015

Additional relevant MeSH terms:
Cardiovascular Diseases
Atorvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors